Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBI1997
- Development stage
- Unknown
- Lead developer
- Saronic Biotechnology
- Modality
- Vaccines & Immunotherapeutics
01
Overview
SBI1997 is a novel immunotherapy candidate being developed by Saronic Biotechnology for the treatment of hepatocellular carcinoma (HCC). It is designed to modulate inhibitory immune cell populations, such as immune-suppressive cells in the tumor microenvironment, to restore and enhance the body's anti-cancer immune response. The drug is currently in Phase 1/2 clinical development, most notably being evaluated in the AUDIT trial (Adjuvant Immunotherapy Trial) for HCC patients who have undergone curative resection or ablation. By targeting the mechanisms of immune evasion, SBI1997 aims to reduce the risk of cancer recurrence and improve long-term survival outcomes in the adjuvant setting.
Beyond the preview
Go deeper on SBI1997.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBI1997.